M&A - IMPACT BIOMEDICAL INC.

Form Type: 10-Q

Filing Date: 2025-05-14

Corporate Action: Acquisition

Type: New

Accession Number: 000164117225010276

Filing Summary: This 10-Q filing by Impact BioMedical, Inc. reports financial results for the quarterly period ended March 31, 2025. The company has experienced an operating loss of $1,010,000 compared to $771,000 for the same period in 2024. Net loss attributable to common stockholders was $1,267,000, which translates to a loss per share of $0.11 for both basic and diluted shares. The financial statements indicate that cash and cash equivalents have decreased from $1,999,000 to $1,318,000. Total assets are reported at $20,051,000 with total liabilities at $13,241,000, resulting in stockholders' equity of $6,810,000. The report reveals the company's ongoing initiatives in biopharmaceuticals and its acquisition of DSS PureAir, Inc. assets, contributing to the company's strategic growth. Additionally, the company has several proprietary technologies under development that may lead to future revenues.